1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms E N Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
1856.065
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R G Connor
|
|
b)
|
Position/status
|
President, Global Vaccines
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
835.687
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Ms D Conrad
|
|
b)
|
Position/status
|
SVP, Human Resources
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
9.069
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr S P Dingemans
|
|
b)
|
Position/status
|
Executive Director
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
0.001
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.8259
|
0.002
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-12
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr J Ford
|
|
b)
|
Position/status
|
SVP & General Counsel
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
0.000034
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 April 2019
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.8259
|
22.812
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-12
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr N Hirons
|
|
b)
|
Position/status
|
SVP, Global Ethics & Compliance
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
839.365
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Jackson
|
|
b)
|
Position/status
|
PCA of Ms S Jackson (SVP,
Global Communications and CEO Office)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
73.793
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs S Jackson
|
|
b)
|
Position/status
|
SVP, Global
Communications and CEO Office
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
112.492
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr B McNamara
|
|
b)
|
Position/status
|
CEO, GSK Consumer Healthcare
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
American Depositary Shares ('ADSs')
ISIN: US37733W1053
|
|
b)
|
Nature of the
transaction
|
Acquisition of ADSs following the re-investment of dividends paid
to shareholders on 11 April 2019
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
$
40.8259
|
947.143
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-12
|
|
f)
|
Place of the
transaction
|
New York Stock Exchange (XNYS)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr D Redfern
|
|
b)
|
Position/status
|
Chief Strategy Officer
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
3072.811
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr R Simard
|
|
b)
|
Position/status
|
President, Pharma Supply Chain
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
590.721
|
||
d)
|
Aggregated
information
Aggregated volume
Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mr P C Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
706.619
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Mrs K Thomson
|
|
b)
|
Position/status
|
PCA of Mr P C Thomson
(President, Global Affairs)
|
|
c)
|
Initial
notification/amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GlaxoSmithKline plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description of the
financial instrument
|
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of the
transaction
|
Acquisition of Ordinary Shares following the re-investment of
dividends paid to shareholders on 11 April 2019.
|
|
c)
|
Price(s) and
volume(s)
|
Price(s)
|
Volume(s)
|
£15.5009
|
154.042
|
||
d)
|
Aggregated
information
Aggregated
volume Price
|
n/a (single transaction)
|
|
e)
|
Date
of the transaction
|
2019-04-15
|
|
f)
|
Place of the
transaction
|
London Stock Exchange (XLON)
|
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: April
16, 2019
|
|
|
|
|
By: VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|